October 18, 2021

The U.S. FDA has announced that Boehringer Ingelheim’s Cyltezo® (adalimumab- adbm) will be automatically interchangeable with its reference product, AbbVie’s Humira® (adalimumab), upon launch in the U.S. market.

  • There are multiple FDA-approved biosimilars for Humira, but to date, Cyltezo is the only one approved as
  • This decision means that pharmacists will be able to dispense Cyltezo as a substitute for Humira, even if the prescription was written for In most cases, prescribers must submit a prescription specifically for a biosimilar for it to be dispensed instead of its reference product.
  • Cyltezo is only the second biosimilar to be approved as automatically interchangeable with its reference product in the United States. The first was Mylan’s Semglee® (insulin glargine-yfgn), a biosimilar to Sanofi’s Lantus® (insulin glargine).
  • Although Cyltezo was FDA approved as a Humira biosimilar in August 2017, it is not expected to be available until 2023 due to a patent
November 19, 2021

COVID-19 Booster Shots Authorized for All Adults

Read More
November 18, 2021

New Warning Added to Climara Pro Prescribing Information

Read More
November 15, 2021

Besremi Approved for Rare Cancer

Read More
November 15, 2021

Mvasi Receives New Cancer Indication

Read More